AmnioAMP vs EpiFix: A Clinician's Side-by-Side Comparison (2026 Update)
AmnioAMP and EpiFix are both dehydrated human amnion/chorion membrane (DHACM) allografts used as advanced wound coverings for stalled or complex wounds. They sit in the same tissue category — human-derived, minimally manipulated amnion/chorion sheets regulated as HCT/Ps under Section 361 of the Public Health Service Act when intended for homologous use — but they are not interchangeable. The practical clinical question is not "which brand wins" but which product fits the wound biology, the clinic's workflow, and the payer pathway. This 2026 update covers what each product is, what the published evidence actually shows (including the newest 2025-2026 data), how handling and coverage differ, and how the CMS CY 2026 flat-rate skin substitute policy changes the economics of that choice.
What the Product Names Mean
- Amniotic membrane allograft — a thin, human-derived membrane graft processed from placental amnion and/or chorion, used as a biologic covering or scaffold in chronic, traumatic, or surgical wounds. - Dehydrated human amnion/chorion membrane (DHACM) — the technical product class for dehydrated, shelf-stable amniotic membrane sheets used in wound care. Both AmnioAMP and EpiFix fall within this class. - AmnioAMP — a DHACM product line for wound care and tissue repair (NextGen Biologics / Stratus BioSystems channels). See the AmnioAMP application protocol for handling and workflow detail. - EpiFix — a registered DHACM product of MiMedx Group, Inc., with the largest published wound-care evidence base in this category. - HCT/P (Section 361) — a human cell or tissue-based product regulated by FDA under the PHS Act, exempt from device/biologic marketing authorization when minimally manipulated and intended for homologous use. Both products follow this pathway.
Evidence Base: What the Trials Actually Compare
No head-to-head randomized trial between AmnioAMP and EpiFix was found in PubMed or ClinicalTrials.gov. Claims that one product is universally superior are therefore not evidence-based. The strongest published evidence for DHACM products in chronic wounds comes from the EpiFix clinical program, which clinicians can use as a category benchmark and then verify against the specific AmnioAMP product literature and IFU.
The landmark EpiFix randomized comparative effectiveness trial in diabetic foot ulcers (Zelen et al., PMID 25424146; NCT01921491) compared dehydrated human amnion/chorion membrane allograft, a bioengineered skin substitute, and standard of care. In the 60-patient trial, 85% and 95% of EpiFix-treated DFUs closed within 4 and 6 weeks, versus 35% and 45% with the bioengineered substitute and 30% and 35% with standard care (all adjusted P ≤ 0.003). Median time to healing was 13 days with EpiFix versus 49 days for both comparators.
A larger 100-patient cohort (Zelen et al., PMID 26695998) reported 12-week closure rates of 97% (31/32) for EpiFix versus 73% (24/33) for the bioengineered substitute and 51% (18/35) for standard care (adjusted P = 0.00019), with a hazard ratio of 5.66 for healing versus standard care. Mean time-to-heal was 23.6 days with EpiFix versus 47.9 days with the substitute. Median graft use was 2.5 per healed wound with EpiFix versus 6 with the substitute, and median graft cost was $1,517 versus $8,918 per healed wound (P < 0.0001).
A confirmatory DFU study (Tettelbach et al., PMID 30136445) randomized 110 patients across 14 wound clinics: dHACM healed 70% of DFUs in 12 weeks by intention-to-treat versus 50% with standard care (P = 0.0338; per-protocol 81% versus 55%, P = 0.0093), with a Cox hazard ratio of 2.15 (95% CI 1.30–3.57).
For venous leg ulcers, a multicenter RCT (Bianchi et al., PMID 29024419) randomized 109 patients to EpiFix plus multilayer compression or compression alone: 60% versus 35% healed at 12 weeks (P = 0.0128) and 71% versus 44% at 16 weeks (P = 0.0065), with a 12-week hazard ratio of 2.26 (95% CI 1.25–4.10).
What changed since the 2015-2019 trial era
The evidence picture has moved in three ways that matter for a 2026 product selection:
1. Network meta-analysis now places dHACM in context. A 2025 network meta-analysis comparing 12 DFU interventions (PMID 40821981) ranks advanced grafts against each other and standard care across randomized evidence — useful for value analysis committees that want the DHACM signal checked against the full intervention field rather than single two-arm trials. 2. The newest dHACM evidence extends to refractory VLUs. A 2026 multicenter cohort in treatment-refractory venous leg ulcers (Nagasaki et al., PMID 41802539) reported 82.7% complete healing in 52 refractory cases, a 52.1% 12-week healing rate, and 90.5% one-year recurrence-free survival — extending the dHACM signal into the hardest VLU subset, and a 2024 cost-effectiveness analysis (Tettelbach et al., PMID 38457298) modeled dHACM in VLUs specifically. 3. Systematic reviews, not single trials, are the payer currency. The 2022 systematic review and meta-analysis of human amniotic membrane products for DFUs (Mohammed et al., PMID 36104736) concluded these products improve healing versus standard care, and a 2021 narrative review (Au et al., PMID 33872365) synthesized the dHACM DFU literature for clinical audiences.
Clinical bottom line: the evidence is strongest for diabetic foot ulcers and is strongest for EpiFix because those trials have been published. For AmnioAMP, clinicians should request product-specific study summaries and match them to the wound type they treat. Absence of published head-to-head data is an evidence gap, not proof of equivalence or inequivalence — a distinction our framework for evaluating a regenerative material addresses in depth.Side-by-Side Comparison
| Factor | AmnioAMP | EpiFix | Clinical implication | |---|---|---|---| | Tissue class | Dehydrated human amnion/chorion membrane allograft | Dehydrated human amnion/chorion membrane allograft | Both are HCT/Ps; verify donor screening and IFU for each | | Manufacturer | NextGen Biologics / Stratus BioSystems | MiMedx Group, Inc. | Check availability and distributor support for your site | | Best-published evidence base | Product-specific case series and IFU indications | Level I RCTs in DFUs (PMID 25424146; NCT01921491) and VLUs (PMID 29024419) | Match the product's literature to the wound type you treat | | Storage and handling | Room-temperature, dehydrated; brief saline rehydration per IFU | Room-temperature, dehydrated; rehydration per IFU | Both avoid cryo/freezer logistics; confirm staff training on each | | Application workflow | Following manufacturer IFU | Following manufacturer IFU | Apply after debridement, hemostasis, and wound bed preparation; see the step-by-step protocol | | HCPCS coding | Q4250 | Product-specific Q-code per current CMS file | Verify the product-to-code mapping before billing | | Payer coverage | Indication-specific; local coverage and medical necessity apply | Indication-specific; local coverage and medical necessity apply | Documentation matters more than brand name | | Regulatory pathway | Section 361 HCT/P | Section 361 HCT/P | Neither is a 510(k) device or 351 biologic; keep claims within homologous use |
Why the Evidence Gap Matters
Sabol et al. (PMID 36032519) argued that standardized reporting of amnion and amnion/chorion allograft data is essential for wound care. Without consistent endpoints, wound-type stratification, and comparator definitions, product-to-product comparisons become unreliable. This is exactly why a page like this cannot responsibly declare AmnioAMP better or worse than EpiFix without head-to-head data. What a clinician can do is compare the evidence behind the specific indication. A diabetic foot ulcer in a well-perfused patient has a stronger evidence base than a mixed venous-arterial ulcer or a traumatic wound. The wound type, not the brand, should drive the choice.
Practical Selection Framework
Before applying either product, confirm the following:
- Wound etiology is established and consistent with the IFU. - Standard of care (debridement, infection control, offloading, compression, moisture balance) has been attempted and documented. - Vascular status is adequate for healing; perfusion has been assessed for lower-extremity wounds. - The wound bed is clean, hemostasis is achieved, and necrosis or biofilm is controlled. - Patient comorbidities (diabetes, PAD, immunosuppression) and wound chronicity are recorded. - Payer coverage criteria for the specific indication have been reviewed. - Staff have been trained on the specific product's handling, hydration, and application steps.
Documentation tip: link the indication, evidence, and prior failed conservative therapy in the same progress note. Payers often deny when these three elements are separated across different documents.Reimbursement Context: The CY 2026 Flat-Rate Era
The CMS CY 2026 Physician Fee Schedule final rule (CMS-1832-F) skin substitute payment restructuring moved most outpatient amniotic membrane products from acquisition-cost-based reimbursement to a standardized flat rate of approximately $127.14 per square centimeter as incident-to supplies. For wound care practices, the economic decision is no longer the per-unit price but the total episode cost: applications used, healing trajectory, clinic visits, and complications. A higher per-unit price can be economically rational if it reduces the total number of applications and accelerates closure; a lower per-unit price is not a bargain if the wound requires more applications or heals more slowly. Carter et al. (PMID 38832861) examined whether cellular and tissue-based products in DFUs have a justifiable cost per square centimeter — under a flat rate, that question shifts from price justification to utilization discipline. HCPCS Q-codes remain product-specific: AmnioAMP-MP maps to Q4250. Verify the product-to-code mapping against the current CMS HCPCS file before billing.
Frequently Asked Questions
What are AmnioAMP and EpiFix?Both are dehydrated human amnion/chorion membrane allografts used as advanced wound coverings. Both are regulated as HCT/Ps under Section 361 of the PHS Act when minimally manipulated and intended for homologous use.
Is there a head-to-head randomized trial comparing AmnioAMP to EpiFix?No PubMed-indexed head-to-head trial was found. The strongest DHACM evidence comes from the EpiFix diabetic foot ulcer trials (PMID 25424146; NCT01921491). For AmnioAMP, rely on the manufacturer IFU and any available product-specific evidence.
Which wound types have the best evidence for amniotic membrane allografts?Diabetic foot ulcers have the strongest evidence base (PMID 36104736; PMID 33872365). Venous leg ulcers have a narrower but positive base (PMID 29024419), now extended to refractory VLUs by 2026 cohort data (PMID 41802539).
How does the 2026 CMS flat-rate policy affect product selection?Under the CY 2026 flat-rate framework (~$127.14/cm²), the deciding economic factor is total episode cost (applications, healing time, complications) rather than per-unit price. Carter et al. (PMID 38832861) evaluated cost per square centimeter justification for cellular and tissue-based products in DFUs.
How should a team apply AmnioAMP-MP correctly?Follow a written protocol: wound-bed preparation, 2-3 minute saline rehydration, side-specific orientation per IFU, non-adherent contact layer plus exudate-matched secondary dressing, and scheduled reassessment. The full sequence is in the AmnioAMP application protocol guide.
What should a wound care team document before applying either product?Wound etiology, duration, measurements, prior standard-of-care therapies with response, vascular status, infection control, offloading/compression plan, and the clinical rationale for selecting an amniotic membrane allograft.
References
1. Zelen CM, et al. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2015;12(6):724-32. PMID: 25424146; ClinicalTrials.gov: NCT01921491. 2. Zelen CM, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J. 2016;13(2):272-82. PMID: 26695998. 3. Tettelbach W, et al. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers. Int Wound J. 2019;16(1):19-29. PMID: 30136445. 4. Bianchi C, et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix) allograft for the treatment of venous leg ulcers. Int Wound J. 2018;15(1):114-122. PMID: 29024419. 5. Mohammed YA, et al. Human amniotic membrane products for patients with diabetic foot ulcers. Do they help? A systematic review and meta-analysis. J Foot Ankle Res. 2022;15(1):63. PMID: 36104736. 6. Tettelbach WH, et al. Dehydrated human amnion chorion membrane to treat venous leg ulcers: a cost-effectiveness analysis. J Wound Care. 2024;33(Sup3):S7. PMID: 38457298. 7. Nagasaki K, et al. Clinical outcomes and prognostic determinants of dehydrated human amnion/chorion membrane for refractory venous leg ulcers. J Vasc Surg Venous Lymphat Disord. 2026;14(4):102473. PMID: 41802539. 8. Comparison of the efficacy of 12 interventions in the treatment of diabetic foot ulcers: a network meta-analysis. 2025. PMID: 40821981. 9. Sabol TJ, et al. Standardized reporting of amnion and amnion/chorion allograft data for wound care. Health Sci Rep. 2022. PMID: 36032519. 10. Au AS, et al. Efficacy of Dehydrated Human Amnion Chorion Membrane in the Treatment of Diabetic Foot Ulcers: A Review. J Am Podiatr Med Assoc. 2021. PMID: 33872365. 11. Carter MJ, et al. Counting the Cost of Cellular and/or Tissue-Based Products in Diabetic Foot Ulcers: Is There a Justifiable Price Limit per Square Centimeter? Adv Wound Care. 2025. PMID: 38832861. 12. ClinicalTrials.gov. DHACM vs Other Commercially Available Treatments. NCT01921491. https://clinicaltrials.gov/study/NCT01921491.
This article is an educational resource for clinicians and healthcare decision makers, not product-specific medical advice. Individual patient outcomes vary. Treatment decisions should be based on the manufacturer's Instructions for Use, clinical judgment, and site-specific factors. Reimbursement information reflects CMS CY 2026 policy effective January 1, 2026; providers should verify current coverage with their local Medicare Administrative Contractor (MAC) and other payers before billing.